Shattuck Labs, Inc. (NASDAQ:STTK – Get Free Report) has been assigned a consensus rating of “Buy” from the thirteen analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $13.70.
A number of brokerages have weighed in on STTK. Leerink Partners initiated coverage on shares of Shattuck Labs in a research report on Monday, July 20th. They set an “outperform” rating and a $16.00 price target for the company. Wall Street Zen lowered shares of Shattuck Labs from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. HC Wainwright decreased their price objective on shares of Shattuck Labs from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. TD Cowen raised shares of Shattuck Labs to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Wedbush lifted their target price on shares of Shattuck Labs from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, October 2nd.
Read Our Latest Report on Shattuck Labs
Institutional Inflows and Outflows
Shattuck Labs Price Performance
Shares of NASDAQ:STTK traded down $0.16 during midday trading on Friday, reaching $4.65. 775,897 shares of the company’s stock were exchanged, compared to its average volume of 964,645. The stock has a market cap of $473.56 million, a price-to-earnings ratio of -9.12 and a beta of 1.21. Shattuck Labs has a fifty-two week low of $1.72 and a fifty-two week high of $8.33. The firm’s 50 day simple moving average is $5.80 and its two-hundred day simple moving average is $6.04.
Shattuck Labs (NASDAQ:STTK – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Equities research analysts predict that Shattuck Labs will post -0.51 earnings per share for the current fiscal year.
Shattuck Labs Company Profile
Shattuck Labs, Inc. is a clinical-stage biotechnology company developing medicines that modulate the immune system to treat cancer. The company’s research has centered on biologic therapies designed to combine immune checkpoint inhibition with activation of immune cells. Its lead candidate, SL-172154, is an engineered fusion protein designed to block the CD47 “don’t eat me” signal and activate CD40, with the aim of promoting an antitumor immune response. Shattuck has evaluated the candidate in clinical studies for cancers including ovarian cancer and higher-risk myelodysplastic syndromes.
Recommended Stories
- Five stocks we like better than Shattuck Labs
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
